Clinical use of digitalis glycosides. An update.
Digitalis glycosides continue to place high on the list of prescribed drugs. Digoxin is 8th on prescriptions written in the United States in 1980, digitoxin 16th, and digitalis leaf 23rd. There is little doubt that most physicians continue to believe these drugs are useful. The application of more definite indications, smaller doses, and the recognition of the role of pharmacokinetics and drug interactions make use of the glycosides more challenging than ever before in 1985.
Doherty
J E
JE
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000367:Age Factors; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents / Q000009:adverse effects; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001682:Biological Availability; D001950:Bretylium Tosylate / Q000627:therapeutic use; D003892:Deslanoside / Q000378:metabolism; D004071:Digitalis Glycosides / Q000009:adverse effects / Q000627:therapeutic use*; D004074:Digitoxin / Q000378:metabolism; D004077:Digoxin / Q000097:blood / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007408:Intestinal Absorption; D007676:Kidney Failure, Chronic / Q000378:metabolism; D008012:Lidocaine / Q000627:therapeutic use; D008657:Metabolic Clearance Rate; D009203:Myocardial Infarction / Q000378:metabolism; D009765:Obesity / Q000378:metabolism; D010672:Phenytoin / Q000627:therapeutic use; D011188:Potassium / Q000378:metabolism; D011660:Pulmonary Heart Disease / Q000378:metabolism; D013959:Thyroid Diseases / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D004071:Digitalis Glycosides; D010672:Phenytoin; D004077:Digoxin; D001950:Bretylium Tosylate; D008012:Lidocaine; D004074:Digitoxin; D011188:Potassium; D003892:Deslanoside